The Stop CMV Act of 2025 adds a new Section 1116A to the Public Health Service Act to create a federal framework for congenital Cytomegalovirus (CMV) screening of newborns. The bill authorizes hospitals and other infant-care entities to test infants 21 days old or younger for congenital CMV, gives state chief health officers authority to prescribe standards and parental notification procedures, and tasks the Advisory Committee on Heritable Disorders in Newborns and Children with a backstop standard-setting role if states do not act within two years.
The bill also directs federal agencies to support implementation and science: HRSA grant funding flows to states that adopt approved standards (to distribute to hospitals/labs), CDC grants target data systems and education, and NIH must expand or establish CMV research programs including diagnostics, interventions, and vaccine work. For professionals, the bill creates regulatory and operational duties for state public-health programs, labs, hospitals, and newborn-care clinicians while shifting follow-up, data, and research priorities at the federal level.
At a Glance
What It Does
The bill permits hospitals and other infant-care entities to test every infant 21 days or younger for congenital CMV and gives state health chiefs authority to set standards for testing, result recording, follow‑up, and parental notification; the federal Advisory Committee steps in if a state fails to act within two years. It also authorizes HRSA grants to states (for distribution to testing entities), CDC grants for data and education, and NIH programs to expand CMV R&D.
Who It Affects
State health departments that operate newborn screening programs, birthing hospitals and newborn nurseries, public-health and clinical laboratories that would perform PCR or other CMV tests, pediatricians and early-intervention services who manage positive infants, and federal agencies (HRSA, CDC, NIH) tasked with grantmaking and research activities.
Why It Matters
The measure creates a national pathway for routine CMV screening without imposing an immediate federal mandate on hospitals, but it reshapes funding priorities and the Advisory Committee’s role. For compliance officers and public-health planners it signals new reporting, consent/notification, laboratory, and follow-up expectations and potential increases in diagnosed infants requiring services.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Stop CMV Act inserts a new section into the Public Health Service Act giving hospitals and comparable infant-care entities the authority to administer CMV tests to every infant who is 21 days old or younger. The bill uses permissive language — it authorizes testing rather than imposing a federal requirement on hospitals — and places the primary design role with each State’s chief health officer, who can issue the operational standards for how and when tests are performed, how results are recorded, how families are informed, and how follow-up is handled.
If states do not adopt standards within two years, the bill empowers the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children to prescribe standards that states may implement. When prescribing or reviewing standards the Advisory Committee must consider other states’ models, existing newborn screening procedures, and relevant scientific evidence — anchoring federal fallback standards to existing practice and evidence rather than inventing wholly new protocols.To support implementation, the bill directs three federal actions.
First, HRSA must award grants to states that adopt the prescribed standards; states then distribute funds to hospitals or other entities to administer tests. Second, CDC grants or cooperative agreements will assist states in building or improving CMV data-collection systems and in producing educational and training materials for clinicians, families, and the public.
Third, NIH must establish or expand research programs focused on screening methods, intervention efficacy, diagnostics, prevention including vaccine research, and other therapeutics during pregnancy and after birth.Finally, the bill amends the Advisory Committee’s statutory duties to explicitly include the CMV screening activities, integrating CMV into federal newborn screening governance. The combination of permissive testing authority, a two‑year state deadline with federal fallback, targeted grant support, and directed research funding creates an incremental but coordinated federal approach to scale detection, data, and science around congenital CMV.
The Five Things You Need to Know
The bill authorizes — but does not mandate — CMV testing by hospitals or infant-care entities for every infant 21 days old or younger.
If a State fails to prescribe approved testing standards within two years, the federal Advisory Committee must issue standards that the State may implement.
HRSA must award grants to States that adopt standards, and those States must distribute funds to hospitals or entities to carry out testing; the bill authorizes appropriations for HRSA grants for FY2025 and FY2026.
CDC grants or cooperative agreements will fund state-level CMV data systems and education/training initiatives; the bill similarly authorizes appropriations for those activities for FY2025 and FY2026.
NIH is required to establish or expand programs for CMV diagnostics, screening‑method studies, intervention efficacy, prevention (including vaccine work), and treatment research during pregnancy and after birth.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Permissive authorization for newborn CMV testing
This subsection gives hospitals and other entities that care for infants up to 21 days old the authority to administer CMV tests to every such infant in their care. Practically, that means institutions may implement universal or targeted screening protocols under state direction, but the federal text does not create a direct federal duty to test individual hospitals or providers.
State standard-setting and parental notification; federal fallback
The bill delegates to each State’s chief executive officer for health the power to devise standards for testing, result recording, follow‑up reviews, tracking, and educational outreach, plus rules for how test results are communicated to parents or guardians. If a State does not adopt standards approved by the Advisory Committee within two years, the Advisory Committee will prescribe standards for that State to use; when doing so the Committee must review other States’ approaches, the State’s existing newborn screening norms, and relevant scientific evidence. This creates a federal backstop while leaving implementation details at the state level.
HRSA grants routed through States to cover testing
The Secretary, through HRSA, must award grants to States that have adopted standards consistent with the statute; those States, in turn, distribute funds to hospitals or other entities to administer tests. The bill authorizes such sums as necessary for fiscal years 2025 and 2026 but does not set a permanent funding stream or per‑test reimbursement rates, leaving allocation mechanics to future appropriation and state decisions.
CDC technical assistance and NIH research priorities
The CDC grant/cooperative‑agreement authority is scoped to build or improve data collection systems and to support education and training for clinicians, patients, and the public, including online evidence‑based materials. NIH must start or expand research on screening techniques, clinical studies of screening and intervention efficacy, diagnostics, prevention and vaccine development, and treatments during pregnancy and infancy. Together these provisions pair near‑term operational support with longer‑term R&D.
Advisory Committee duty expansion
The bill amends the Advisory Committee’s statutory duties to add responsibility for carrying out activities under the new CMV screening section. Functionally, this ties the Committee—already the federal technical body for newborn screening policy—into CMV program design, standard review, and the two‑year fallback mechanism described above.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Infants with congenital CMV and their families — earlier detection increases the chance of timely audiology screening, antiviral consideration, and referral to developmental and early‑intervention services. Early diagnosis can change clinical trajectories where interventions exist.
- State public‑health programs — the bill supplies grant funding and federal technical assistance to build CMV data systems and public education, improving surveillance and program capacity.
- Researchers and vaccine developers — a directed NIH mandate to expand CMV diagnostics and vaccine research creates new institutional support and potential study populations, improving likelihood of funded trials and translational work.
- Pediatricians and audiologists — clearer screening pathways and state standards should streamline identification and referral for infants at risk of CMV‑related hearing loss and developmental delay.
- Public‑health laboratories that scale up PCR or molecular testing capacity — they gain predictable demand and federal‑supported programs that can offset some start‑up costs.
Who Bears the Cost
- Hospitals, birthing centers, and newborn nurseries — even though testing is authorized (not mandated) they will face operational decisions, specimen‑collection costs, lab fees, and potential staffing or consent‑process burdens if they choose to screen.
- State health departments — the law charges chief health officers with developing standards, overseeing implementation, and distributing HRSA funds; those duties require administrative capacity and potential matching or maintenance funds.
- Clinical and public‑health laboratories — increased throughput may require equipment, personnel, validation studies, and quality assurance investments that precede reimbursement.
- Early‑intervention and specialty care providers — identifying more CMV‑positive infants will increase demand for audiology, neurology, and developmental services, straining local service capacity without parallel funding.
- Federal agencies (HRSA, CDC, NIH) — the bill authorizes appropriations and new program work, which will compete for limited agency budgets and require Congress to provide sufficient funding beyond the two fiscal years explicitly mentioned.
Key Issues
The Core Tension
The central dilemma is whether and how to scale early identification of congenital CMV—so that infants who can benefit from monitoring and intervention are found—without imposing unsustainable costs, uneven implementation, and clinical uncertainty from imperfect tests; the bill tries to thread that needle by authorizing testing and funding support while leaving state‑level discretion, but that design risks both unequal access and fragmented technical standards that could limit public‑health impact.
The bill takes a federated approach: it authorizes testing but leaves primary implementation to states, with the Advisory Committee as a two‑year backstop. That design reduces immediate federal imposition but creates uneven adoption risk — states with limited resources or competing priorities could defer, producing a patchwork of access.
The two‑year trigger transfers responsibility to an Advisory Committee whose standards the statute ties to existing state practices and scientific evidence, but the law does not specify the clinical testing modality (saliva PCR, dried blood spot PCR, or other assays), case definitions, or confirmatory testing algorithms. Those technical choices will materially affect false‑positive rates, lab capacity needs, and clinical follow‑up pathways.
Funding is another key uncertainty. The bill authorizes unspecified sums “as may be necessary” for HRSA and CDC grants in FY2025 and FY2026 and directs NIH to expand research programs, but it does not create a multi‑year, indexed funding stream or require sustained appropriations for state testing or downstream services.
If Congress does not fund the authorized activities at meaningful levels, states or hospitals could bear startup costs, and the program could underperform. Finally, broader operational issues — parental consent protocols, data privacy and reporting safeguards, and coordination with existing newborn screening panels — are delegated to states, which may produce inconsistent consent regimes and reporting standards across jurisdictions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.